SCHEMBL8308233

SCHEMBL8308233

CC(=O)OC1CCCc2ccc([N+](=O)[O-])cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 5/20 0.47
DRD2 P14416 5/20 0.47
HTR7 P34969 5/20 0.47
HSP90AA1 P07900 1/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPC1 O15118 2/20 0.41
POLB P06746 2/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 1/20 0.41
HIF1A Q16665 1/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
PDE7A Q13946 1/20 0.39
PDE7B Q9NP56 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8312961 0.96 HSP90AA1 (0.46) CHRM4DRD2HTR7HSP90AA1MEN1
SCHEMBL8311548 0.92 DRD2 (0.46) CHRM4DRD2HTR7HSP90AA1CYP3A4
SCHEMBL6988386 0.80 CYP3A4 (0.44) DRD2HSP90AA1CYP3A4CYP2C9CYP2C19
SCHEMBL15540339 0.79 CYP19A1 (0.42) HSP90AA1MEN1KMT2ACYP3A4CYP2C19
SCHEMBL6811167 0.78 CHRM4 (0.50) CHRM4DRD2HTR7
SCHEMBL394579 0.77 MEN1 (0.54) HSP90AA1MEN1KMT2ANPC1POLB
SCHEMBL8566869 0.77 HSP90AA1 (0.47) HSP90AA1MEN1KMT2ANPC1POLB
SCHEMBL23174865 0.77 HCRTR1 (0.50) MEN1KMT2APOLBALDH1A1LMNA
SCHEMBL30290988 0.76 IDO1 (0.58) CHRM4DRD2HTR7MEN1KMT2A
SCHEMBL4455923 0.76 IDO1 (0.58) CHRM4DRD2HTR7MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004087124-A1 COMPOUNDS HAVING SEROTONIN 5-HT17 RECEPTOR ANTAGONIST ACTIVITY AND MUSCARINIC M4 RECEPTOR AGONIST ACTIVITY AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MITSUBISHI PHARMA CORPORATION (JP) 2004-10-14 WO disclosed